Overview

A Study to Evaluate the Safety and Efficacy of ION373 in Patients With Alexander Disease (AxD)

Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ION373 in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.
Phase:
Phase 3
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.